EUCTR2016-002358-18-FR进行中（未招募）1 期
Phase II study of first line treatment of Chronic Graft versus Host Disease with Arsenic Trioxide - GvHD-ATO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Medsenic
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult patients (=18 years) who have received a first allogeneic stem cell transplantation for a hematological disease (any source of hematopoietic stem cells is authorized; any category of conditioning regimen prior to allo-SCT is authorized; any type of stem cell donors is authorized)
- •2. Confirmed diagnosis of a first episode of chronic GvHD requiring systemic immunosuppressive therapy (any prior GvHD prophylaxis previously used is accepted). Chronic GvHD diagnosis is defined according to the NIH Working Group Consensus. Chronic GvHD diagnosis will be based on the evaluation of the severity of the different clinical manifestations including:
- •a/ Performance status evaluation
- •b/ Cutaneous evaluation measured by the percentage of extension or the presence of sclerotic features. If relevant, confirmation with a biopsy should be performed whenever possible
- •c/ Oral symptoms
- •d/ Ocular symptoms
- •e/ Gastro-intestinal symptoms
- •f/ Evaluation of liver involvement (total bilirubin, transaminases and alkaline phosphatases)
- •g/ Pulmonary function evaluation
- •h/ Evaluation of the musculoskeletal manifestations, especially the amplitude of the relevant articulations
- •i/ Genital tract symptoms
- •3. Signed informed consent
- •4. Absence of contra-indications to the use of ATO
- •5. Subjects affiliated with an appropriate social security system?
- •6. Women who are of childbearing potential must have a negative serum pregnancy test and agree to use a medically acceptable method of contraception throughout the study and for 3 months following the end of the study
- •7. Patient not participating or not having participated in a clinical study in the 30 days prior to his/her inclusion in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •1. Patient developing acute GvHD (whether early or late onset” form)
- •2. Patients developing overlap GvHD as defined by the 2014 NIH Working Group Consensus (presence of one or more acute GvHD manifestations in a patient with a diagnosis of chronic GvHD)
- •3. A mild” form of chronic GvHD not requiring systemic immunosuppressive therapy
- •4. A moderate” form of chronic GvHD limited to one organ site not requiring systemic immunosuppressive therapy
- •5. Patient receiving mycophenolate mofetil
- •6. GvHD occurring following donor lymphocytes infusion (DLI)
- •7. Not the first episode of chronic GvHD needing systemic immunosuppressive therapy
- •8. Second allogeneic stem cell transplant
- •9. Significant arrhythmias, electrocardiogram (EKG) abnormalities:
- •a/ Congenital QT syndromes
- •b/ History or presence of significant ventricular or atrial tachyarrhythmia
- •c/ Clinically significant resting bradycardia (< 50 beats per minutes)
- •d/ QTc > 480 msec on screening EKG (using the QTcF formula)
- •e/ Right bundle branch block plus left anterior hemiblock, bifascicular block
- •10. Central or peripheral neuropathy
- •11. Neutrophils < 0.5 × 109/L
- •12. Platelets < 50 × 109/L
- •13. Uncontrolled systemic infection which in the opinion of the investigator is associated with an increased risk of the patients’ death within 1 month after the start of therapy
- •14. Severe neurological or psychiatric disorders
- •15. Denied informed consent
- •16. Pregnancy
研究者
相似试验
进行中（未招募）
不适用
Phase II study of first line treatment of chronic graft versus host disease with the association of ciclosporine, corticosteroids and Rituximab - R-GVHDChronic graft versus host diseaseMedDRA version: 12.1Level: LLTClassification code 10066261Term: Chronic graft versus host diseaseEUCTR2009-016898-14-FRCHU de Nantes
招募中
不适用
Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial)Patients with locally advanced pancreatic cancer (BR-A or UR-LA) scheduled for pancreatic resectionJPRN-UMIN000046618Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama45
招募中
2 期
Phase-2 clinical trial on the treatment of chronic dysphagia in head and neck cancer patients with dedicated strengthening exercises using the Swallow Exercise AidDysphagiaswallowing impairment10027656NL-OMON42230Antoni van Leeuwenhoek Ziekenhuis20
进行中（未招募）
不适用
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and RituximabTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphomaEUCTR2005-000693-45-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
已完成
2 期
Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000030457Fujita Health University School30